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Poor transdermal penetration of active pharmaceutical ingredients (APIs) impairs both bioavailability
and therapeutic benefits and is a major challenge in the development of transdermal drug delivery sys-
tems. Here, we transformed a poorly water-soluble drug, etodolac, into an ionic liquid in order to improve
its hydrophobicity, hydrophilicity and skin permeability. The ionic liquid was prepared by mixing etodo-
lac with lidocaine (1:1, mol/mol). Both the free drug and the transformed ionic liquid were characterized
by differential scanning colorimetry (DSC), infrared spectroscopy (IR), and saturation concentration mea-
surements. In addition, in vitro skin-permeation testing was carried out via an ionic liquid-containing
patch (Etoreat patch). The lidocaine and etodolac in ionic liquid form led to a relatively lower melting
point than either lidocaine or etodolac alone, and this improved the lipophilicity/hydrophilicity of etodo-
lac. In vitro skin-permeation testing demonstrated that the Etoreat patch significantly increased the skin
permeation of etodolac (9.3-fold) compared with an etodolac alone patch, although an Etoreat patch did
not increase the skin permeation of lidocaine, which was consistent with the results when using a lido-
caine alone patch. Lidocaine appeared to self-sacrificially improve the skin permeation of etodolac via its
transformation into an ionic liquid. The data suggest that ionic liquids composed of approved drugs may
substantially expand the formulation preparation method to meet the challenges of drugs which are
characterized by poor rates of transdermal absorption.
 2016 The Authors. Published by Elsevier B.V. This is anopenaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely
used for various inflammatory diseases. The side effects of NSAIDs
include the risk of digestive tract disorders, kidney function
impairment, and liver function impairment, and these are consid-
ered a problem when there is a need for frequent use [1,2]. Accord-
ingly, parenteral administration methods have been developed.
Some methods have adopted the form of an external preparation
for the transdermal absorption of NSAIDs [3–8]. A patch of Keto-
profen, which is referred to as the Mohrus Patch, is a typical suc-
cessful example. However, skin permeability of some NSAIDs is
extremely poor. Therefore, the therapeutic effects are remarkably
decreased in cases of external administration by comparison with
oral administration. Therefore, an improvement in the technology
of the skin permeability of NSAIDs is required.Ionic liquids are defined as organic salts, which are character-
ized by melting points that are below 100 C [9,10]. Ionic liquids
that are liquid at ambient temperatures and pressures are referred
to as room-temperature ionic liquids [11]. Ionic liquids are used as
solvents in chemistry and in catalysis during synthesis, and their
use has been extended to pharmaceutical applications with the
ultimate goal of improving the dissolution, solubility and bioavail-
ability of active pharmaceutical ingredients (APIs) [12–14]. Sahbaz
et al. [15] demonstrated that transformation of the weakly basic,
poorly water-soluble drugs, itraconazole, cinnarizine and halo-
fantrine, into lipophilic ionic liquids facilitates incorporation into
lipid-based formulations and improves their bioavailability via
lipid absorption pathways after oral administration. In addition,
ionic liquids have sparked interest for their use as additives in for-
mulations for topical drug delivery [16–21].
Hough and co-workers [22,23] have used ionic liquid in the
preparation of several compounds that combine biologically active
cations and anions. The cations of lidocaine, ranitidine, and dide-
cyldimethyl ammonium are capable of forming ionic liquids, while
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been approved by the FDA for use in pharmaceutical applications.
Together, these are used to form three ionic liquids: lidocaine-
docusate, ranitidine-docusate, and didecyldimethyl ammonium-
ibuprofen. Lidocaine-docusate combines the cation lidocaine with
the anion docusate (an emollient) to produce an ionic liquid that
has shown better efficacy than free lidocaine as a topical anesthe-
sia. Ranitidine-docusate combines the same anion with the cation
ranitidine, which is a histamine H2-receptor antagonist, and pro-
vides an advantage over ranitidine alone that allows the avoidance
of problems with polymorphism and impurities. Didecyldimethyl
ammonium-ibuprofen has shown anti-inflammatory and antibac-
terial properties that can be associated with the use of anions
and cations, respectively. These developments led us to the
assumption that NSAIDs themselves might create an ionic liquid
with the counter ion of another API and consequently increase
the skin permeability and therapeutic efficacy of each.
Etodolac, an anionic ion of NSAID, is known to reduce the levels
of hormones that cause inflammation and pain in the body [24]. It
is used to treat mild to moderate pain, osteoarthritis, or rheuma-
toid arthritis [25]. Lidocaine, a cationic ion, is used to numb tissue
in a specific area and to treat ventricular tachycardia. It can also be
used for nerve blocks [26]. Etodolac and lidocaine might be good
candidates for ionic liquid formation. In the present study, there-
fore, we tried to prepare an ionic liquid by mixing etodolac and
lidocaine (1:1, mol/mol). The transformed ionic liquid was charac-
terized by differential scanning colorimetry (DSC), infrared spec-
troscopy (IR) and saturation concentration measurements. In
addition, in vitro skin-permeation testing was carried out with
ionic liquid-containing patches (Etoreat patch).
2. Materials and methods
2.1. Materials
Etodolac and lidocaine were purchased from ABIC Inc. (Netanya,
Israel) and Delta Synthetic Co., Ltd. (New Taipei City, Taiwan),
respectively. Propylene glycol, diethyl sebacate and 1-octanol were
purchased from Wako Pure Chemical Industries, Ltd. (Osaka,
Japan).
2.2. Etodolac–Lidocaine salt preparation
The Etodolac–Lidocaine ionic liquid was obtained by mixing an
equimolar mass of etodolac and lidocaine at 60 C until each was
completely dissolved.
2.3. DSC analysis
DSC measurement was performed on an EXSTAR6000 (Seiko
Instruments Inc., Chiba, Japan) using a sample pan made of alu-
minum. The temperature range was 100 to 200 C, and the heat-
ing rate was adjusted at 5 C/min. All samples were kept at room
temperature before the DSC measurement.
2.4. IR analysis
Fifty mg each of the Etodolac–Lidocaine ionic liquid, the etodo-
lac, and the lidocaine was dissolved in 0.5 mL of chloroform to gain
chloroform solutions. In addition, 50 mg each of the Etodolac–Lido-
caine ionic liquid, the etodolac, and the lidocaine was dissolved in
1 mL of propylene glycol to gain propylene glycol solutions. Each
sample of the chloroform and propylene glycol solutions was held
between sodium chloride plates to measure the infrared absorp-
tion spectrum. IR spectral measurements were carried out using
an Infrared Spectrophotometer (IRPrestige-21; Shimadzu, Kyoto,Japan). The optical resolution was 2 cm1 and the data were accu-
mulated 20 times. Using the spectrum data of each solution, the
wave numbers (cm1) of the carbonyl groups in the carboxylic acid
in the etodolac, the carbonyl groups of amides in the lidocaine, the
carbonyl groups of carboxylate anions (ACOO), and the amides in
the Etodolac–Lidocaine ionic liquid all were compared, and thereby
the presence/absence of salt formulation in the Etodolac–Lidocaine
ionic liquid was determined.
2.5. HPLC
The concentration of etodolac and lidocaine was determined
using an HPLC system equipped with a UV detector (LC-2010C
HT; Shimadzu). Chromatographic separation was performed using
a YMC-Pack Pro C18 RS (5 lm, 4.6  150 mm i.d.; YMC Co., Ltd.,
Kyoto, Japan) at 40 C. The mobile phase was 0.18% sodium lauryl
sulfate in a 0.1% phosphoric acid solution/acetonitrile/methanol
(50/40/10, v/v) at a flow rate of 1.0 mL/min. The wavelength of
the UV detector was set at 225 nm. The retention times for the
lidocaine and etodolac were approximately 8 and 14 min,
respectively.
2.6. Solubility determination
The saturation solubility of etodolac and lidocaine in water was
determined. An excess of each of the Etodolac–Lidocaine ionic liq-
uid, the etodolac, and the lidocaine was added to 5 mL deionized
water in 10 mL glass vials and then sealed. The vials were placed
in a shaker water bath and agitated at 60 oscillations/min at
25 C. The samples were withdrawn after 24 h, then filtered, and
assayed for drug concentrations using HPLC, as described above.
The saturation solubility of etodolac and lidocaine in propylene
glycol, diethyl sebacate or 1-octanol was also determined.
2.7. Patch preparation
To prepare the Etoreat patches, Etodolac–Lidocaine ionic liquid,
solvents, formulation bases, PSA matrix, and hexane were mixed at
60 C. A general casting method was used to prepare a PSA tape
(150 lm thickness) containing 4.4% Etodolac–Lidocaine ionic liq-
uid. An etodolac-alone patch (E-alone patch) and a lidocaine-
alone patch (L-alone patch) were also prepared using the same
method.
Each Etoreat patch contained 4.4% Etodolac–Lidocaine ionic liq-
uid. The E-alone patch contained 2.4% etodolac only and the L-
alone patch contained 2.0% lidocaine only.
2.8. Skin preparation
Frozen Yucatane Micro Pig (YMP) skin sets (female pigs:
5 months old) were obtained from Charles River Japan Inc. (Yoko-
hama, Japan). Each YMP skin set consisted of 16 skin sheets (sheet
size: approximately 10  10 cm) enclosed in a plastic bag identi-
fied by number.
To prepare the intact YMP skin sheet, subcutaneous fat was
removed from the purchased YMP skin and the skins were der-
matomed to a nominal thickness of approximately 1 mm using
an electric dermatome (KED-101; Keisei Medical Industries Co.,
Ltd., Tokyo, Japan). The prepared YMP skin sheets were stored at
20 C until use. Before starting the skin-permeation tests, the fro-
zen YMP skin sheets were thawed at room temperature and cut
into 25 mm rounds.
To prepare the stripped YMP skin sheet, tape stripping was per-
formed 30 times using Scotch tape (BK-18; 3M Japan Ltd., Tokyo,
Japan) on the intact YMP skin sheet 25 mm rounds immediately
before the skin-permeation tests.
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The skin-permeation tests were performed using Franz-type
diffusion cells (effective diffusional area: 1.0 cm2, PermeGear Inc.,
Hellertown, USA) [27]. The intact YMP skin or the stripped YMP
skin was used for the permeation tests. The YMP skin was mounted
on receptor cells filled with 8.0 mL of 0.01 M phosphate buffered
saline (PBS, pH 7.4). The receptor cell was maintained at 32 C by
a constant-temperature circulator water bath. After equilibrating
for 10–30 min, transepidermal water loss (TEWL) was measured
using a Vapometer (SWL4001JT; Delfin technologies Ltd., Cuopio,
Finland) and a Standard Adapter (Delfin technologies Ltd.). After
TEWL measurement, the YMP skin was removed from the receptor
cell. Each of the Etoreat, E-alone and L-alone patches (1.1 cm2,
diameter: 12 mm) was applied to the skin surface. The receptor cell
medium was maintained at 32 C and stirred with a Teflon stirrer
driven by a constant speed motor at 1000 rev/min throughout
the test. The receptor fluid (0.2 mL) was withdrawn at 2, 4, 8,
and 24 h for the test with the intact YMP skin or at 0.25, 0.5,
0.75, 1, 1.5, 2, and 3 h for the test with the stripped YMP skin.
The same volume of fresh PBS was added to the receptor cell to
keep the volume constant. Samples were filtered using a cellulose
acetate membrane (0.45 lm pore size, Advantec Toyo Kaisha, Ltd.,
Tokyo, Japan), and were assayed for drug concentration using
HPLC, as described above. The cumulative amount of drug perme-
ation was calculated using the following formula:
Qsðlg=cm2Þ ¼ Csn Vs=Asþ
Xn1
i¼1
Csi S=As
Qs: The cumulative amount of drug permeated per unit area
(lg/cm2).
Csn: Concentration of drug (lg/mL) determined in the receptor
fluid at nth sampling interval.
Vs: Volume of the receptor cell chamber (mL), 8.0 mL.
Pn1
i¼1 Csi: Cumulative drug concentrations in the receptor fluid
from the first sampling to the n  1th sampling.
S: Volume of the sampling (mL), 0.2 mL.
As: Effective diffusional area (cm2), 1.0 cm2.
2.10. Determination of drug content in the skin
After the in vitro skin-permeation testing, the YMP skin was
removed from the diffusion cell and then divided into stratum cor-
neum, epidermal and dermis to determine the drug content in each
of the skin factions. To obtain stratum corneum from the YMP skin,
tape stripping was performed 10 times using Scotch tape (BK-18;
3M Japan Ltd.). The epidermal was obtained by shaving it from
the stripped YMP skin. To obtain dermis from the YMP skin, the
shaved YMP skin was cut into an effective diffusion area and then
into pieces using scissors. Each of the stratum corneum, the epider-
mal, and the dermis samples was suspended in 2 mL of methanol,
and then sonicated for 5 min to extract the drugs (etodolac and
lidocaine). After centrifugation at 1500g for 10 min, the resultant
supernatant was filtered with a nitrocellulose membrane
(0.45 lm pore size, Merck Millipore, Ltd., Billerica, USA), appropri-
ately diluted with methanol, and assayed for drug content in each
of the skin factions using HPLC, as described above.
2.11. Calculation of permeation parameters
The skin-permeation parameters of the drugs were calculated
using SKIN-CAD [28] on the basis of the results of in vitro intact
skin and stripped skin-permeation testing as well as testing for
drug release. SKIN-CAD is simulation software for the skin and
body pharmacokinetics following transdermal and topical drugdelivery. This software can optimize the design of transdermal
drug delivery systems (prediction of clinical performance and
setup of administration schedule) as well as evaluation of the
effects of various factors on skin permeation and blood concentra-
tion profiles. The drug-release tests were performed using a disso-
lution apparatus (NTR-6100A; Toyama Sangyo Co., Ltd., Osaka,
Japan). The paddle rotation speed was set at 50 rpm with 900 mL
of 0.025 M phosphate buffer (32 C, pH 6.8). Each of the patches
was cut into 30 mm rounds that were applied to an adhesive on
a stainless steel disk (diameter: 41.2 mm; Toyama Sangyo Co.,
Ltd.). The release liner was peeled off and the disk assembly was
carefully placed in the dissolution vessel parallel to the paddle
blade with the adhesive side up. Dissolved solutions were with-
drawn at 1, 3, 6, and 24 h and assayed for drug concentration using
HPLC, as described above.
For the calculations, the skin (thickness of stratum corneum,
20 lm; thickness of whole skin, 1 mm) and patch design parame-
ters (thickness of the matrix, 150 lm; etodolac concentration in
the matrix, 2.28 mg/cm3; lidocaine concentration in the matrix,
1.87 mg/cm3) were also considered. The mean steady-state fluxes
and lag times of the drugs through the intact and stripped YMP
skin were calculated using SKIN-CAD based on the results of the
skin-permeation testing. In addition, the diffusion coefficients for
the matrix of each patch, stratum corneum and viable skin sample
were calculated using SKIN-CAD based on the results of the skin-
permeation and drug-release testing.
2.12. Statistics
All data are reported as the mean ± S.D. Statistical analyses of
the data were conducted using a Welch t test.
3. Results
3.1. Characterizations of the Etodolac–Lidocaine ionic liquid
The transformation of the Etodolac–Lidocaine ionic liquid was
achieved by mixing equimolar masses of powdered etodolac and
powdered lidocaine under the heated conditions described above.
Fig. 1 shows the IR spectra of etodolac powder, lidocaine pow-
der and Etodolac–Lidocaine ionic liquid. In Etodolac–Lidocaine
ionic liquid, the absorption bands characteristic to C@O stretching
of the carboxyl group of etodolac powder were diminished and a
new band appeared at about 1,573 cm1 (Table 1). This provided
strong evidence of the salt formation in the Etodolac–Lidocaine
ionic liquid.
Fig. 2 displays the DSC thermograms of Etodolac–Lidocaine
ionic liquid, free etodolac, free lidocaine, and a mixture of etodolac
and lidocaine. In the free etodolac and free lidocaine, sharp
endothermal peaks were found at the melting points: 148 and
60 C, respectively. These peaks disappeared, however, though a
broad endothermal peak that was due to the eutectic point that
persisted in the mixture of etodolac and lidocaine. In addition, no
peak was observed in the Etodolac–Lidocaine ionic liquid. This sug-
gests that the Etodolac–Lidocaine ionic liquid, which is a salt of
etodolac (148 C) and lidocaine (60 C), has no melting point and
the Etodolac–Lidocaine ionic liquid is different from a mixture of
etodolac and lidocaine.
3.2. Saturation solubility
To study the changes in the hydrophilicity/lipophilicity when
an ionic liquid is formed, the saturation solubilities of etodolac
and lidocaine were determined for several solvents. Etodolac was
only scarcely dissolved in water, while lidocaine completely dis-
solved in water (Fig. 3). The saturated concentration of lidocaine
Fig. 1. IR Spectra of Etodolac–Lidocaine ionic liquid in propylene glycol. Each of the samples of the etodolac alone (A), the lidocaine alone (B), and the Etodolac–Lidocaine
ionic liquid (C) (50 mg) was dissolved in 1 mL of propylene glycol to gain a propylene glycol solution. Each sample was held between sodium chloride plates. IR spectral
measurements were carried out using an Infrared Spectrophotometer (IRPrestige-21). The optical resolution was 2 cm1 and the data were accumulated 20 times.
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Table 1
IR absorption bands for carbonyl group (C@O stretching, cm1).
Compound Assignment Wave number (cm1)
In chloroform In propylene glycol
Etodolac ACOOH 1707 1711
Lidocaine ACONR2 1675 1665
Etodolac–lidocaine ACOOA Not clear 1573
CONR2 1676 1680
Fig. 2. DSC thermograms of the Etodolac–Lidocaine ionic liquid. DSC measurement
was performed on an EXSTAR6000 using a sample pan made of aluminum.
The temperature range was 100 to 200 C, and the heating rate was adjusted to
5 C/min. All samples were kept at room temperature before DSC measurement.
Fig. 3. Solubility of Etodolac–Lidocaine ionic liquid in water. Excess of Etodolac–
Lidocaine ionic liquid, etodolac alone and lidocaine alone was added to 5 mL
deionized water in 10 mL glass vials, which were then sealed. The vials were placed
in a shaker water bath and agitated at 60 oscillation/min at 25 C. The samples were
withdrawn at 24 h, then filtered, and assayed for drug concentration using HPLC as
described in Section 2. The saturation solubility of etodolac and lidocaine in
propylene glycol, diethyl sebacate or 1-octanol was also determined. Data represent
the mean ± S.D. (n = 4).
Table 2
Comparisons of the Etodolac–Lidocaine, etodolac and lidocaine.
Saturation solubility (mM)
Etodolac Etodolac in Etodolac–L
In water 0.3 ± 0.0 28.8 ± 0.2
In propylene glycol 224.6 ± 2.2 >700
In diethyl sebacate 378.2 ± 70.9 >700
In octanol 298.0 ± 102.9 >700
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increased the saturation solubility of both etodolac and lidocaine
in water: 28.8 ± 0.2 mM for etodolac and 31.7 ± 0.2 mM for lido-
caine (Table 2). The values for the saturation solubility of lidocaine
alone in propylene glycol, diethyl sebacate and octanol were essen-
tially high (>700 mM), while those of etodolac alone were quite
low. Surprisingly, the saturation solubility of etodolac in propylene
glycol, diethyl sebacate and octanol was markedly improved when
it formed an ionic liquid with lidocaine. These results clearly indi-
cate that values for the hydrophilicity and lipophilicity of etodolac
and the hydrophilicity of lidocaine were increased via the transfor-
mation into an ionic liquid.
3.3. Skin permeation
In order to compare the skin permeability of the Etodolac–Lido-
caine ionic liquid with that of etodolac alone and lidocaine alone,
in vitro permeation tests through intact YMP skin or stripped
YMP skin with three different patches (Etoreat (a patch containing
Etodolac–Lidocaine ionic liquid), E-alone patch and L-alone patch)
were carried out. Fig. 4A and B shows the time course profiles of
the cumulative permeated amounts of etodolac and lidocaine
through the intact YMP skin. The Etoreat patch induced signifi-
cantly higher etodolac permeation over 24 h after patch applica-
tion compared with the E-alone patch (p < 0.01) (Fig. 4A). On the
other hand, the cumulative permeated amounts of lidocaine from
the Etoreat patch at 24 h after application (441 ± 91 nmol/cm2)
were similar to, or even lower than, those from the L-alone patch
(566 ± 91 nmol/cm2).
Table 3 summarizes the skin-permeation parameters for etodo-
lac in the E-alone patch and in the Etoreat patch, and it lists the
parameters for lidocaine in the L-alone patch and in the Etoreat
patch, as calculated on the basis of the data shown in Fig. 4. As
for etodolac, the etodolac steady-state flux of the Etoreat patch
through intact YMP skin was 9.3-fold larger than that of the
E-alone patch. The etodolac lag time for the skin permeation by
the Etoreat patch through the intact YMP skin was 1.6-fold shorter
than that of the E-alone patch. The etodolac diffusion coefficient in
the matrix of patches, stratum corneum and viable skin for the
Etoreat patch was approximately 11.0, 5.5 and 0.9-fold larger than
that of the E-alone patch. As for lidocaine, the lidocaine steady-
state flux of the Etoreat patch through the intact YMP skin was
0.8-fold smaller than that of the L-alone patch. However, the lag
time for the skin permeation of lidocaine in the Etoreat patch
through the intact YMP skin became 1.5-fold shorter than that of
the L-alone patch. The values for the lidocaine diffusion coefficient
in the matrix of patches, stratum corneum and viable skin of the
Etoreat patch were approximately 0.5-, 4.0- and 1.1-fold larger
than those of the L-alone patch.
3.4. Drug content in skin factions
In order to compare the skin distribution values of the Etodo-
lac–Lidocaine ionic liquid, the etodolac alone, and the lidocaine
alone, the drug content in the stratum corneum, the epidermal,idocaine Lidocaine Lidocaine in Etodolac–Lidocaine
17.4 ± 0.2 31.7 ± 0.2
>700 >700
>700 >700
>700 >700
Fig. 4. Skin-permeation profile for (A) etodolac in Etoreat (d) and E-alone (h), and
(B) lidocaine in Etoreat (d) and L-alone (h). The skin-permeation tests were
performed using Franz-type diffusion cells. Either intact YMP skin or stripped YMP
skin was used. Each of the Etoreat patch, the E-alone patch, and the L-alone patch
(1.1 cm2, diameter: 12 mm) was applied to the skin surface mounted on receptor
cells filled with 8.0 mL of 0.01 M phosphate buffered saline (PBS, pH 7.4),
maintained at 32 C. Receptor fluid (0.2 mL) samples were withdrawn at indicated
time points. The samples were assayed for drug concentration using HPLC as
described in Section 2. The cumulative amounts of drug permeation were
calculated, as described in Section 2. Data represent the mean ± S.D. (n = 4).
⁄p < 0.05, #p < 0.05 and ⁄⁄p < 0.01.
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testing (Fig. 5 and Table 4). The etodolac content in each of the skin
factions was significantly higher in the Etoreat patch than in the
E-alone patch at 2, 8 and 24 h (Fig. 5A and B and Table 4). The etodo-
lac content in the stratum corneum in the Etoreat patch at 2, 8 and
24 h was approximately 4.6, 4.2 and 4.0-fold higher, respectively,
than that in the E-alone patch. The lidocaine content in each skin
faction was lower in the Etoreat patch than in the L-alone patch
at 8 and 24 h, although the amounts at 2 h were almost the same
(Fig. 5C and D and Table 4). These results are well reflected by
the differences in the time course profiles of the cumulativeTable 3
Comparisons of permeation parameters of Etodolac–Lidocaine, etodolac and lidocaine.
Eto
In
Steady-state flux through intact skin (nmol/cm2/h) 1.1
Time lag across intact skin (h) 4.9
Steady-state flux through stripping skin (nmol/cm2/h) 5.6
Time lag across intact skin (h) 1.1
Diffusion Coefficient (cm2/h  106) Matrix 0.9
Stratum corneum 0.4
Viable skin 14
Matrix/skin partition coefficient 12
Stratum corneum/viable skin partition coefficient 17permeated lidocaine amounts of the Etoreat and L-alone patches
shown in Fig. 4B. Interestingly, in the Etoreat patch
(Fig. 5B and D and Table 4), the amount of etodolac and lidocaine
in each skin faction was similar, although the cumulative amounts
that had permeated and the steady-state fluxes were different
(Fig. 4 and Table 3). The results described in Figs. 4 and 5 and in
Tables 3 and 4 indicate that the lidocaine in the Etoreat patch con-
tributed to an increase in the skin permeation of etodolac as a
result of the formation of ionic liquid. The lidocaine in the Etoreat
self-sacrificially reduced the limits of etodolac permeation through
the matrix and the stratum corneum. However, the skin perme-
ation of the lidocaine in the Etoreat was slightly decreased com-
pared with that of lidocaine alone.4. Discussion
We successfully prepared an ionic liquid by combining an anio-
nic NSAID, etodolac, with a cationic counter ion API, lidocaine. The
transformation to an ionic liquid improved the lipophilicity/
hydrophilicity of both APIs, etodolac and lidocaine, as we assumed
it would. The IR Spectra and DSC thermographs of the Etodolac–
Lidocaine ionic liquid indicated that salt formation occurred in
the ionic liquid and did not result in API degradations (Figs. 1
and 2). Solubility improvement in ionizable APIs usually is subject
to salt screening with sodium, and ionic liquid formulation of APIs
has been reported by combining counter ions such as tetra-
butylphosphonium (TBP) [29]. Hence, this study represents the
first production of an ionic liquid by utilizing the interactions
between API molecules with opposite charges.
The saturation level of solubility for etodolac and lidocaine in
water was increased to 82.7 and 1.7-fold, respectively, via the for-
mation of ionic liquid (Table 2). The formation of ionic liquids, in
principle, reduces the melting point, which increases both the dis-
sociation rate and the solubility [23,29–31]. Our finding is consis-
tent with previous reports [22,23,32,33]. However, it seems that
such an improvement cannot necessarily be achieved by the for-
mation of an ionic liquid. Hough et al. [23] demonstrated that
the combination of the relatively hydrophobic lidocaine cation
with a hydrophobic anion, docusate, forms a hydrophobic ionic liq-
uid salt, lidocaine-docusate, and exhibits reduced water solubility.
Balk et al. [29] showed that the respective counter ions control the
balance between desired properties (either increased kinetic solu-
bility or a faster dissolution rate in most situations) and undesired
properties (either decreased kinetic solubility or a slower dissolu-
tion rate in most situations). The creation of an ionic liquid with
the desired properties requires either the selection of a suitable
counter ion for an API or the combination of respective APIs with
opposite charges.
Interestingly, the saturation solubility of etodolac in propylene
glycol, diethyl sebacate and octanol was also markedly improved
by the formation of an ionic liquid with lidocaine (Table 2). Thedolac Lidocaine
E-alone In Etoreat In L-alone In Etoreat
10.5 26.3 19.4
3.0 1.8 1.2
24.3 200.8 64.1
1.2 0.5 0.4
10.4 40.0 18.7
2.5 1.5 5.8
94 1390 3568 3769
.5 5.3 2.0 8.3
.3 8.8 7.0 5.9
Fig. 5. Drug content in the skin factions: (A) Etodolac in E-alone, (B) Etodolac in Etoreat, (C) Lidocaine in L-alone, and (D) Lidocaine in Etoreat. After the in vitro skin-
permeation testing, the YMP skin was removed from the diffusion cell and then divided into stratum corneum, epidermal and dermis. Each of the samples, stratum corneum,
epidermal and dermis, was suspended in 2 mL of methanol, and sonication was applied for 5 min to extract the drugs (etodolac and lidocaine). After centrifugation followed
by filtration, the drug content in each of the skin factions was determined via HPLC, as described in Section 2. Data represent the mean ± S.D. (n = 4).
Table 4
Comparisons of the amount of drugs in skin factions.
Faction Time (h) Drug content in skin factions (nmol)
Etodolac Lidocaine
In E-alone In Etoreat In L-alone In Etoreat
Stratum corneum 2 11.1 ± 1.5 51.5 ± 9.9** 43.5 ± 9.1 58.5 ± 4.0
8 21.2 ± 0.8 88.4 ± 11.1**,$ 142.1 ± 12.4 70.0 ± 6.2##
24 20.5 ± 2.8 82.1 ± 7.1**,$ 133.1 ± 36.5 52.1 ± 15.8#
Epidermal 2 0.3 ± 0.5 3.8 ± 1.4*,$$ 11.1 ± 4.1 8.5 ± 1.7
8 3.1 ± 0.8 16.7 ± 2.0**,$ 19.2 ± 10.0 13.2 ± 0.3
24 2.8 ± 0.5 19.8 ± 4.7**,$ 47.4 ± 57.6 12.4 ± 2.4
Dermis 2 0.3 ± 0.6 3.8 ± 2.1* 17.1 ± 20.2 10.2 ± 4.6
8 4.9 ± 2 17.1 ± 5.5* 50.8 ± 7.5 22.6 ± 5.2##
24 5.2 ± 1.7 25.8 ± 10.9* 73.0 ± 4.9 30.3 ± 9.1##
Sum of the each fractions 2 11.7 ± 0.7 59.3 ± 11.7**,$ 71.6 ± 28.9 77.6 ± 5.9
8 29.2 ± 2.4 122.3 ± 17.6** 212.2 ± 18.2 105.5 ± 7.6##
24 28.6 ± 2.7 127.5 ± 15.2**,$ 253.2 ± 25.5 95.0 ± 11.0##
Each value represents the mean ± S.D. (n = 4).
* p < 0.05 significant difference from E-alone for etodolac content using the Welch t test.
** p < 0.01 significant difference from E-alone for etodolac content using the Welch t test.
# p < 0.05 significant difference from L-alone for lidocaine content using the Welch t test.
## p < 0.01 significant difference from L-alone for lidocaine content using the Welch t test.
$ p < 0.05 significant difference from lidocaine content in Etoreat using the Welch t test.
$$ p < 0.01 significant difference from lidocaine content in Etoreat using the Welch t test.
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(Table 2). Lidocaine has a cationic amino group in its structure,
while etodolac has an anionic carboxyl group. The ionic liquid of
etodolac and lidocaine was formed through the ionic association
between the cationic group of lidocaine and the carboxyl groupof etodolac with a suitable mixing molecular ratio at 1:1. The ionic
groups of etodolac and lidocaine were coated with hydrophobic
portions of ions, which neutralized the etodolac and lidocaine com-
plex. The neutralization due to the interaction between etodolac
and lidocaine might have increased the hydrophobicity of etodolac,
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organic solvents (Table 2).
The formation of an ionic liquid with etodolac and lidocaine at
an equimolar ratio also influenced the skin permeation of both
APIs. Interestingly, the ratio of 1:1 created a neutralized ionic liq-
uid complex that increased the skin permeation of etodolac and
decreased that of lidocaine (Fig. 5C and D and Table 4). The lido-
caine in the Etoreat patch (containing ionic liquid) appeared to
self-sacrificially improve the limiting steps, and, thereby, the per-
meation of etodolac through the matrix and stratum corneum of
skin. The underlying mechanism behind the improved skin per-
meation was not clear, but both APIs might stay together in the
skin as ion pairs or clusters rather than as independent solvated
ions because the molar ratio of etodolac to lidocaine in each of
the skin factions approximated 1 (Table 4). This theory has been
suggested by molecular dynamics simulation studies [34–36] and
spectroscopic investigations via NMR techniques [36,37] indicat-
ing that ionic liquids do not dissolve as independent ions, but,
instead, maintain a nanostructured organization in aqueous
media.
The application of ionic liquids has been extended from sol-
vents in chemistry and catalysis for synthesis to pharmaceutical
applications with the ultimate goal of improving the dissolution,
solubility and bioavailability of APIs [23,30,38–40]. Inactive coun-
ter ions are the usual choice when creating an ionic liquid. In the
present study, the API lidocaine seemed to demonstrate a dual
functionality in improving the skin permeability of etodolac.
The transport of etodolac through the skin was improved by its
formation of an ionic liquid with lidocaine, which would improve
the pharmacological activity. However, the approach explored in
this study may be restricted because the skin permeability of
lidocaine itself was reduced by the formation of an ionic liquid
with etodolac. In order to study the pharmacological activities
of etodolac and lidocaine in the Etoreat patch, therefore, some
preclinical studies with animal models are now being conducted
by our group.5. Conclusions
We successfully prepared an ionic liquid by combining an anio-
nic NSAID, etodolac, with a cationic counter ion, lidocaine. The
transformation of the ionic liquid improved the lipophilicity/
hydrophilicity of etodolac and increased the skin permeation of
etodolac (9.3-fold). Lidocaine appeared to self-sacrificially improve
the skin permeation of this acidic and poorly water-soluble drug,
etodolac, by transforming it into a 1:1 ionic liquid.Conflict of interests
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